Follow
Paul Chapman
Paul Chapman
Unknown affiliation
Verified email at mskcc.org
Title
Cited by
Cited by
Year
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ...
New England Journal of Medicine 364 (26), 2507-2516, 2011
90992011
Inhibition of mutated, activated BRAF in metastatic melanoma
KT Flaherty, I Puzanov, KB Kim, A Ribas, GA McArthur, JA Sosman, ...
New England Journal of Medicine 363 (9), 809-819, 2010
42682010
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
H Peinado, M Alečković, S Lavotshkin, I Matei, B Costa-Silva, ...
Nature medicine 18 (6), 883-891, 2012
38802012
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
A Hauschild, JJ Grob, LV Demidov, T Jouary, R Gutzmer, M Millward, ...
The Lancet 380 (9839), 358-365, 2012
34972012
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
G Bollag, P Hirth, J Tsai, J Zhang, PN Ibrahim, H Cho, W Spevak, C Zhang, ...
Nature 467 (7315), 596-599, 2010
20202010
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ...
Nature 487 (7408), 500-504, 2012
19562012
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E)
PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ...
Nature 480 (7377), 387-390, 2011
16342011
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
GA McArthur, PB Chapman, C Robert, J Larkin, JB Haanen, R Dummer, ...
The lancet oncology 15 (3), 323-332, 2014
12052014
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
F Su, A Viros, C Milagre, K Trunzer, G Bollag, O Spleiss, JS Reis-Filho, ...
New England Journal of Medicine 366 (3), 207-215, 2012
11992012
Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at …
TZ Horvat, NG Adel, TO Dang, P Momtaz, MA Postow, MK Callahan, ...
Journal of Clinical Oncology 33 (28), 3193, 2015
10872015
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
GV Long, U Trefzer, MA Davies, RF Kefford, PA Ascierto, PB Chapman, ...
The lancet oncology 13 (11), 1087-1095, 2012
10202012
KIT as a therapeutic target in metastatic melanoma
RD Carvajal, CR Antonescu, JD Wolchok, PB Chapman, RA Roman, ...
Jama 305 (22), 2327-2334, 2011
10132011
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
PB Chapman, LH Einhorn, ML Meyers, S Saxman, AN Destro, ...
Journal of Clinical Oncology 17 (9), 2745-2745, 1999
9941999
Evolutionary dynamics of cancer in response to targeted combination therapy
I Bozic, JG Reiter, B Allen, T Antal, K Chatterjee, P Shah, YS Moon, ...
elife 2, e00747, 2013
6882013
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort …
JL McQuade, CR Daniel, KR Hess, C Mak, DY Wang, RR Rai, JJ Park, ...
The Lancet Oncology 19 (3), 310-322, 2018
5382018
The advantages of targeted protein degradation over inhibition: an RTK case study
GM Burslem, BE Smith, AC Lai, S Jaime-Figueroa, DC McQuaid, ...
Cell chemical biology 25 (1), 67-77. e3, 2018
5342018
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
EW Joseph, CA Pratilas, PI Poulikakos, M Tadi, W Wang, BS Taylor, ...
Proceedings of the National Academy of Sciences 107 (33), 14903-14908, 2010
5092010
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival
GY Ku, J Yuan, DB Page, SEA Schroeder, KS Panageas, RD Carvajal, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2010
4922010
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial
RD Carvajal, JA Sosman, JF Quevedo, MM Milhem, AM Joshua, ...
Jama 311 (23), 2397-2405, 2014
4542014
Cross-presentation of disialoganglioside GD3 to natural killer T cells
DY Wu, NH Segal, S Sidobre, M Kronenberg, PB Chapman
The Journal of experimental medicine 198 (1), 173-181, 2003
3692003
The system can't perform the operation now. Try again later.
Articles 1–20